Klinik für Dermatologie

Universitätsklinik der Paracelsus Medizinischen Privatuniversität

Dr. Dirk Debus Dr. med. Dirk Debus, Oberarzt

Oberarzt der Klinikambulanz
Koordinator des Hauttumorzentrums

Tel: 0911-398-2044
E-Mail: debus@klinikum-nuernberg.de
Fax: 0911-398-7097

Prof.-Ernst-Nathan-Str. 1
90419 Nürnberg
Deutschland
Haus: Hautklinik Haus 16, 4. Etage

Qualifikationen

Weiterbildung

Zusatzbezeichnungen

Zertifizierungen

Weiterbildungsbefugnis

Aktuelle Arbeitsschwerpunkte

Frühere Arbeitsschwerpunkte

[nach oben]

Mitgliedschaften und Engagement

[nach oben]

Publikationen

Weispfenning G, Debus D, Paul E (2005) Hochdosierte Immunglobulintherapie bei therapieresistenter Druckurtikaria. JDDG 3 Suppl 1; 151

Debus D, Schmidt S, Paul E (2007) Erfolgreicher Einsatz von Rituximab bei therapieresistentem Pemphigus vulgaris. JDDG 5 Suppl 2; 217

Debus D, Jacobi A, Paul E (2007) Anti-TNFa-Therapie bei Druckurtikaria. Erfolgreicher Einsatz von Infliximab bei therapieresistenter verzögerter Druckurtikaria. Allergo J 16; 507-511

Jacobi A, Debus D, Schuler G, Hertl M (2008) Infliximab in a patient with refractory mucosal aphthosis. JEADV 22 (1); 109-110

Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M (2008) Rituximab exerts a dual effect in Pemphigus vulgaris. Journal of Investigative Dermatology 128, 2850–2858

Debus D, Schnuch A, Szliska C, Uter W; Facial allergic contact dermatitis. Data from the IVDK and review of literature. IVDK. Hautarzt. 2009 Jan;60(1):13-21. doi: 10.1007/s00105-008-1644-6. Link

Debus D (2010) Abteilung Haut und Liebe – Die Geschichte der Hautklinik am Klinikum Nürnberg. Akt Dermatol 36: 268-277 Link

Debus D, Schultz ES (2012) Aktuelle Therapie des Basalzellkarzinoms. Akt Dermatol 38(7): 265-271

Debus D (2012) Dermatologische Onkologie – State of the Art. Kompendium Dermatologie 8(1): 6-8

Debus D (2013) Dermatologische Onkologie – State of the Art. Kompendium Dermatologie 9(1): 12-14 Link

Debus D (2013) Modern Management of Basal Cell Carcinom, J DTSCH DERMATOL GES., vol 11: 55-57

Livingstone E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, Rompel R, Trefzer U, Nashan D, Kilian K, Debus D, Kähler KC, Mauerer A, Möllenhoff K, Dippel E, Schadendorf D (2015) Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study.  Br J Dermatol 172(6):1646-50 

Corrie P, Terheyden P, Tije A, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson M, Goodman G, Sadetsky N, Rutkowski P (2015) A Prospective Observational Safety Study of Patients With BRAFV600 Mutation–Positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (Zelboraf Safety Study [ZeSS]): Interim Results; Oral Presentation, EADO, Marseille.

Neumaier J, Debus D (2015) Fortgeschrittenes Melanom: Checkpointinhibitoren im Vergleich. Focus Onkologie;11: 43-44.

Doesch J, Debus D, Meyer C, Papadopoulos T, Schultz E, Ficker J, Brueckl W (2016) Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer; 95, 35-38.

Debus D (2016) Prof. Ernst Wilhelm Nathan; 25. Fortbildungswoche für praktische Dermatologie und Venerologie, München Poster.

Treiber N, Huber MA, Schneider LA, Scharffetter-Kochanek K, Schultz E, Debus D (2017) Intermittent vemurafenib therapy in malignant melanoma. JDDG 15(4): 451-454 Link

Debus D (2017) Prof. Dr. Ernst Wilhelm Nathan (23. 5. 1889 – 1. 11. 1981). Akt Dermatol; 43(03): 110-112 Link

Corrie P, Terheyden P, ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson MLG, Goodman GR, Sadetsky N, Colburn D, Rutkowski P (2018) A prospective observational safety study of patients (pts) with BRAFV600‐mutated unresectable or metastatic melanoma (mM) treated with vemurafenib (VEM) (Zelboraf safety study [ZeSS]): final results. Pigment Cell Melanoma Res.; 31:144-145

Krieter M, Schultz E, Debus D (2018) Update zum Basalzellkarzinom. Onkologie heute 4/2018 Link                                                                                              

Lauterbach B, Kakkassery V, Debus D, Heindl LM, Schultz ES (2018) Advanced periocular basal cell carcinoma-a therapeutic challenge, Ophthalmologe 2018 May 17, doi: 10.1007/s00347-018-0734-9 Link 

Berking, C; Weichenthal, M; Gutzmer, R; Schadendorf, D; Leiter, U; Mohr, P; Haferkamp, S; Huber, M; Loquai, C; Kiecker, F; Feldmann-Boddeker, I; Debus, D A non-interventional, multi-center, prospective Study for combined Treatment of advanced Melanoma with Dabrafenib and Trametinib in a practical Everyday Life ("real-world setting"): COMBI-r, J DTSCH DERMATOL GES. 2017; 15: 52-53.

Krieter M, Lauterbach B, Debus D (2018) Autoimmune Pancreatitis with diabetic Ketoacidosis with PD1 Inhibition. J DTSCH DERMATOL GES. 2018; 16: 57-57.

Graml J, Eglmeier J, Debus D, Schultz E (2018) EBV-positive diffuse large cell B-cell Lymphoma - a new and rare Entity, J DTSCH DERMATOL GES. 2018; 16: 32-32.

Corrie PG., Terheyden P, ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska‐Morawiec M, Freivogel K, Munson MLG, Goodman GR, Hsu JJ, Sadetsky N, Colburn D, Rutkowski P (2018) A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study) BJD 29 Nov 2018 Link

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel J.C, Berking C, Kaehler K.C, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D , Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost E.G, Meier F (2019) Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases, European Journal of Cancer 110 (2019) 11-20 Link

Baron, J m, Grabbe J, Ludwig A et al. Contact sensitization to plants of the Compositae family: Data of the Information Network of Departments of Dermatology (IVDK) from 2007 to 2016 (vol 80, pg 222, 2019) Contact Dermatitis. 2019 Apr;80(4):222‐227. Link

Krieter M, Schultz E, Debus D (2019) Das maligne Melanom, MMW Fortschritte in der Medizin 10/2019 Link

Graml J, Debus D, Schultz E, et al. Atypical Vascular Proliferation after Radiatherapy - Post-radiotherapy Angiosarcoma (Aug 2019) J DTSCH DERMATOL GES, 17: 86-86. 

Berking C; Livingstone E, Weichenthal M, et al. Interim Analysis of the Efficacy and Safety of Dabrafenib and Trametinib in Patients with metastatic Melanoma in daily clinical Practice (COMBI-r) (Aug 2019) J DTSCH DERMATOL GES, 17: 72-73.

Haferkamp S, Alter M, Debus D, et al. Therapeutic Reality of Patients with BRAF-mutated advanced/metastatic Melanoma in Germany and Austria (Aug 2019) J DTSCH DERMATOL GES, 17: 71-72.

Enzelsberger K, Debus D, Schultz E, et al. Multicentric Sentinel Healthcare Research Project of Skin Cancer Centers in Nuremberg, Erlangen, Regensburg and Wuerzburg (Aug 2019) J DTSCH DERMATOL GES, 17: 68-68.

Eglmeier J, Debus D, Schultz E, et al. Chronic lymphocytic Leukemia (CLL): Negative Predictor of Therapy Response to PD-1-Inhibition in advanced cutaneous Squamous Cell Carcinoma (cSCC)? (Aug 2019) J DTSCH DERMATOL GES, 17: 41-41.

Berking C; Livingstone E, Weichenthal M, et al. Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study.  (Oct  2019) Annals of oncology , 30: 544+. Link

Amaral T.,Kiecker F.,Schaefer S, Stege H,Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F,  Karoglan A, Posch C, Gambichler T, Pfoehler C,  Thoms K, Tietze J, Debus D, et al.(2020) Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients BJD 30 Mar 2020

Eglmeier J, Debus D, Schultz E, et al. (Jan 2020) PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia: a case series and literature review European J of Dermatology Vol 30: 69-71.

Haferkamp S, Alter M, Wolf I, Debus D, et al. (Feb. 2020) Treatment Reality of Patients with BRAF-Mutant Advanced/Metastatic Melanoma in Germany, Austria and Switzerland in the Era of Choice, Oncology research a treatment 43: 177

Haferkamp S, Alter M, Debus D, Schilling B, Pinter A, Terheyden P, Utikal JS, Sachse MM, Haalck T, Wolf IH. Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice. Adv Ther. 2020 Aug;37(8):3619-3629. doi: 10.1007/s12325-020-01430-x. Epub 2020 Jul 8.PMID: 32638206 Link

Heratizadeh A, Werfel T, Schubert S, Geier J, Debus D; Contact sensitization in dental technicians with occupational contact dermatitis. Data of the Information Network of Departments of Dermatology (IVDK) 2001-2015. IVDK. Contact Dermatitis. 2018 Apr;78(4):266-273. doi: 10.1111/cod.12943. Epub 2018 Jan 12.PMID: 29327359 Link

Weichenthal M, Stadler R, Schley G, D. Debus et al. E-health meets "Real World": App-based Support in the adjuvant Therapy of Melanoma Patients in Stage III with Dabrafenib and Trametinib (Combi-EU), JDDG, Volume: ‏', Sup: 2, Page ‏ 2, Meeting Abstract,‏ FV45, Aug 2020

Hecker C, Becker A,Lauterbach B, D. Debus et al.,Immunohistochemical Analysis for Identification of possible Biomarkers for the Checkpoint Inhibition for advanced Melanoma, JDDG, Vol: ‏', Sup: ‏ 2, Page: ‏ 3, Meeting Abstract: ‏ P16, Aug 2020

Krieter M, Debus D, Schultz E, Cerebral Radionecrosis - A diagnostic and therapeutic Challenge, JDDG, Vol: ‏ 18, Sup: 2 ‏, Pages: ‏ 37-38, Meeting Abstract: ‏ P24, Aug 2020

Schalk J, Debus, D, Schultz, E, Opportunities and Limits of Teledermatology, JDDG, Vol: 18; Pages: 63-63; Sup: 2; Meeting Abstract: P82; Aug 2020

Graml J, Debus, D, Schultz E, et al. Ophthalmic Side Effects - A Case Series on Targeted Melanoma Therapy and Immunotherapy, JDDG, Vol: ‏ 1, Sup: ‏ 2, Page: ‏ 69, Meeting Abstract: ‏ P100, Aug 2020

Schalk J, Debus D, Schultz E, Toxic epidermal Necrolysis (TEN) with combined Immunochemotherapy, JDDG, Vol: ‏ 18, Sup: 2, Page ‏ 72, Meeting Abstract: ‏ P105, Aug 2020

Berkenkamp M, Debus D, Schultz E, Hedgehog Inhibitor Vismodegib for unresectable and metastatic Basal Cell Carcinoma, JDDG, Vol:  18, Sup: 2 , Page: ‏ 77, Meeting Abstract: ‏ P119, ‏ Aug 2020

Goetz J, Storz L, Debus D, et al. Concurrently existing chronic lymphocytic Leukemia appears to be associated with a poorer Response in Patients with advanced cutaneous Squamous Cell Carcinoma to an Immunotherapy with PD-1 Antibodies, JDDG, Volume: 18, Sup: ‏ 2, Page: ‏ 7, Meeting Abstract: ‏ P 126, Aug 2020

Berking C, Schadendorf D, Weichenthal M, Debus D, et al. Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases, JDDG, Vol: ‏18, Sup: 2, Pages: ‏ 80-81, Meeting Abstract: ‏ P128, Aug 2020

Richtig E, Debus D, Stadler R, et al. Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM, JDDG, Vol: ‏18, Sup: 2, Pages:  81-82, Meeting Abstract: ‏ P130 , Aug 2020

Burda B, Finkenzeller W, Debus.D, Schultz E, et al. GBS-imitating vasculitic Neuropathy in a Patient with metastatic Melanoma under Therapy with Vemurafenib and Cobimetinib JDDG, Vol: ‏18, Sup: 2, Page: ‏ 82, Meeting Abstract: ‏ P131, Aug 2020

Berking C, Schadendorf D, Weichenthal M, Debus D, Gutzmer R,  Leiter-Stöppke U,  Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases, Annals of Oncology, Volume 31, Sup: 4, Page S755, Sep 2020 Link

Steeb T, Wessely A, Alter  M, Bayerl  C, Bender A, Bruning  G, Dabrowski E, Debus D et al. Patterns of care and follow‑up care of patients with uveal melanoma in German‑speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG), German Dermatologic Cooperative On; Comm Ocular Melanoma, J. Cancer Res, Nov 2020 Link

Adjuvant melanoma treatment: real-world data from the DACH region
Schumann, K; Mangana, J; Dummer, R; Sindrilaru, M; Reinhardt, L; Meier, F; Gutzmer, R; Schatton, K; Amaral, T; Eigentler, T; Peitsch, W; Hillen, U; Ziller, F; Debus, D; Maul, L; Weishaupt, C; Borger, S; Haferkamp, S; Terheyden, P; Thiem, A; Sachse, M; Ollinger, A; Hotzenecker, W; Heppt, M; Hansel, G; Posch, C
EXP DERMATOL. 2021; 30(3): E25-E26.

Grimmelmann I, Momma M, Debus D ,Berking C, Kochanek C, et al. Lipase elevation and type 1 diabetes mellitus related toimmune checkpoint inhibitor therapyeA multicentrestudy of 90 patients from the German DermatooncologyGroup EJC,-9 (2021) 1-10, Mai 2021 Link

 

 

[nach oben]

 
Es öffnet sich eine Seite auf klinikum-nuernberg.de mit Notfallinformationen
Bitte spenden sie


AbstandhalterMarke Stadt Nürnberg

Übersicht

Aktuelles

Unternehmen

Bildung

Partner

Service

Zentren